Alzheimer’s disease (AD) is a typical progressive neurodegenerative disease, mainly manifesting as severe cognitive dysfunction, and involving memory, thought processes, and emotion. The kynurenine pathway (KP) is one of the main metabolic pathways of tryptophan, which can be divided into neurotoxicity and neuroprotective branches. Increasing evidence has suggested that KP is involved in the pathogenesis of AD. This review considers the role of KP in the pathogenesis of AD, with reference to the relevant literature on KP interventions in AD in the PubMed database. The result will provide an important reference for the use of KP as a target for AD drug development.